Table 3.
Statin and ACEI/ARB Effects on Composite NPZ-3 Scores in Marginal Structural Modelsa
| Drug Effect on NPZ-3 Score | Estimate (95% CI) | P Value |
|---|---|---|
| Statin causal effect | ||
| Year 1 | 0.025 (−0.043 to .093) | .47 |
| After year 1 (per year) | −0.012 (−0.029 to .005) | .16 |
| Years since baseline | 0.061 (.057–.065) | <.001 |
| Statin causal effect, censored at ACEI/ARB initiation | ||
| Year 1 | −0.029 (−.102 to .045) | .45 |
| After year 1 (per year) | −0.008 (−.27 to .011) | .38 |
| Years since baseline | 0.063 (.059–.068) | <.001 |
| ACEI/ARB causal effect | ||
| Year 1 | −0.068 (−.14 to .008) | .08 |
| After year 1 (per year) | −0.005 (−.027 to .017) | .65 |
| Years since baseline | 0.064 (0.060–.068) | <.001 |
| ACEI/ARB causal effect, censored at statin initiation | ||
| Year 1 | −0.111 (−.211 to −.012) | .03 |
| After year 1 (per year) | 0.007 (−.029 to .043) | .71 |
| Years since baseline | 0.064 (0.059–.068) | <.001 |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval NPZ-3, z score of averaged Trailmaking (Tr) A and B and digit symbol test (DST).
aModels adjusted for baseline age, sex, race, language, education level, smoking status, dyslipidemia, cardiovascular disease or diabetes, CD4+ T-cell count, human immunodeficiency virus type 1 RNA level <400 copies/mL, body mass index, estimated glomerular filtration rate, and hypertension.